Literature DB >> 29231172

Cefazolin and coagulation disorders: a case report.

Eugénie Gay1, Anne Barthel1, Nicolas Rouzic2, Basile Henriot2, Baptiste Quélennec3, Aurélien Lorleac'h2, Nathalie Prades1, François Schmitt1.   

Abstract

We report the case of a 79-year-old patient, admitted to the department of infectious diseases at Bretagne Sud Hospital Center for a right calcaneal osteitis, complicated by a pacemaker leads infectious endocarditis. Meticillin sensitive Staphylococcus aureus was documented by blood culture. Antibiotic treatment was established using intravenous cefazolin for an initial 6 weeks period. Prothrombin time (PT) decreased as well as vitamin K dependent factors, without anticoagulation therapy, at day 7 of cefazolin treatment. After bleeding occurred on calcaneal osteitis, the VAC® therapy system was removed and intravenous vitamin K 10 mg (then 5 mg per day for 5 days per os) was administered. Vitamin K allowed PT and vitamin K dependent factors to return to normal values. Literature review does not explicitly mention the effects on vitamin K dependent factors after cefazolin administration. Four severe haemorrhagic episodes under cefazolin have been declared in France so far since February 2017. The goal of this article is to alert clinicians and clinical pathologists from the potential appearance of coagulation disorders in patients treated by cefazolin.

Entities:  

Keywords:  cefazolin; hypoprothrombinemia; monitoring; vitamin K

Mesh:

Substances:

Year:  2018        PMID: 29231172     DOI: 10.1684/abc.2017.1314

Source DB:  PubMed          Journal:  Ann Biol Clin (Paris)        ISSN: 0003-3898            Impact factor:   0.459


  3 in total

1.  Impact of genetic and clinical factors on warfarin therapy in patients early after heart valve replacement surgery.

Authors:  Boxia Li; Ruisheng Liu; Chengqi Wang; Changan Ren; Shiming Zhang; Fan Zhang; Jianping Zhang; Shidong Liu; Yuhui Wei; Wenjing Liu; Bing Song; Xinan Wu
Journal:  Eur J Clin Pharmacol       Date:  2019-08-23       Impact factor: 2.953

2.  Coagulation disorders during treatment with cefazolin and rifampicin: rare but dangerous.

Authors:  Ines Kouki; Clémence Montagner; Wladimir Mauhin; Jonathan London; Thierry Lazard; Sylvie Grimbert; Valérie Zeller; Olivier Lidove
Journal:  J Bone Jt Infect       Date:  2021-04-01

3.  A cell-based high-throughput screen identifies drugs that cause bleeding disorders by off-targeting the vitamin K cycle.

Authors:  Xuejie Chen; Caihong Li; Da-Yun Jin; Brian Ingram; Zhenyu Hao; Xue Bai; Darrel W Stafford; Keping Hu; Jian-Ke Tie
Journal:  Blood       Date:  2020-08-13       Impact factor: 25.476

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.